Zhanguo Li, MD, PhD

Professor of Rheumatology, Chief, Department of Rheumatology and Immunity

Director, Center of Clinical Immunology

Director, Institute of Rheumatology and Immunology

Medical School of Peking University, Beijing, China

Professor Zhanguo Li obtained his medical degree from the First Millitary Medical University, China, followed by postgraduate training at the Faculty of Medicine, University of Sydney. He then worked as a Research Fellow in Immunopathology at Dana-Farber Institute, Harvard University Medical School prior to his current role at Peking University Medical School.

Professor Li is the President of Clinical Immunology Association of China, the Honorary President of Chinese Rheumatology Association (CRA), the Past President of Asian and Pacific League Against Rheumatism (APLAR). He is also the Past President of International League of Associations for Rheumatology (ILAR). He is currently the Associate Editor of Clinical Rheumatology, and Associate Editor of International Journal of Rheumatic Disease, the Chief Editor of Chinese Journal of Rheumatology, and the Chief Editor of Chinese Journal of Clinical Immunology and Rheumatology. In addition, he serves on the editorial boards of Nat Rev Rheum, Ann Rheum Dis, Curr Opin Rheum, and Clin Exp Rheum. He has published over 500 articles on peer reviewed journals, e.g. Nat Med, Nat Genet, Immunity, Cell H&M, Ann Internal Med, Nat Rev Rheum, and Ann Rheum Dis. He has contributed as Chief-Editor or author to over 30 textbooks and book chapters in Rheumatology and Immunology.

He is the founder of International Forum of Rheumatoid arthritis which has been held annually since 2009. He has received a number of national and international acclaim for his dedication to rheumatology.

Professor Li played a leading role in development of classification criteria for early rheumatoid arthritis (ERA), and in establishing of a diagnostic model for Sjögren's syndrome (SS) by novel biomarkers. He developed by using low-dose IL2, small-pulse of cyclophasphamide and T cell vaccine treatment of SLE, and the PRINT strategy for high remission in RA.